Verma S, Cam M C, McNeill J H
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
J Am Coll Nutr. 1998 Feb;17(1):11-8. doi: 10.1080/07315724.1998.10718730.
A growing body of experimental and clinical research indicates that the trace element, vanadium, exerts potent insulin-mimetic effects in vitro and in vivo when used in pharmacological doses. Since our first demonstration of the anti-diabetic and cardioprotective effects of vanadium in vivo, impressive advances have been made in our understanding of its mechanism of action, pharmacokinetics and pharmacodynamics. A major advance in the use of vanadium as an insulin-mimetic has been the development of organic vanadium complexes which are 2 to 3 times as potent as inorganic vanadium and have been extensively studied in our laboratory. There is an emerging role for the use of vanadium in human diabetes and the recently conducted clinical trials support this contention. The present review summarizes some of the key aspects of vanadium biology which exemplify the potent insulin-mimetic, anti-diabetic and antihypertensive effects of this intriguing trace element.
越来越多的实验和临床研究表明，微量元素钒在以药理剂量使用时，在体外和体内均具有强大的胰岛素模拟作用。自从我们首次证明钒在体内具有抗糖尿病和心脏保护作用以来，我们对其作用机制、药代动力学和药效学的理解取得了令人瞩目的进展。作为胰岛素模拟物使用钒的一个重大进展是有机钒配合物的开发，其效力是无机钒的2至3倍，并且已经在我们实验室中进行了广泛研究。钒在人类糖尿病治疗中的应用正逐渐崭露头角，最近进行的临床试验支持了这一观点。本综述总结了钒生物学的一些关键方面，这些方面体现了这种有趣的微量元素强大的胰岛素模拟、抗糖尿病和抗高血压作用。
